The stimulation of quiescent cells with growth factors induces widespread changes in gene expression, including the activation of promoters controlled by the transcription factor AP-1 (30) . Following the binding of growth factors to cell surface receptors, a protein kinase cascade is activated, which generally results in the activation of two kinases termed ERK1 and ERK2. ERK1 and ERK2 belong to a family of kinases known as extracellular signal-regulated kinases (ERKs) or mitogen-activated protein (MAP) kinases (12) . Both ERKI and ERK2 are activated by phosphorylation on specific threonine and tyrosine residues (44) . This phosphorylation is catalyzed by a threonine/tyrosine kinase known as MEK (MAP and ERK kinase) (15, 16, 53, 54, 57) . MEK itself is activated by phosphorylation on uncharacterized serine and/or threonine residues by both c-Raf-1 or MEK kinase (17, 28, 31, 32, 58) . c-Raf-1 appears to couple this cascade to Ras (39, 51, 52, 56) , while MEK kinase may be activated by a distinct mechanism (32) . ERK1 and ERK2, as well as MEK1, can be deactivated in vitro by treatment with the serine/threonine specific phosphatase type 2A (PP2A), which dephosphorylates the activat-ing threonine in ERK1 and ERK2, and the activating serines and threonines in MEK1 (1, 4, 7, 22, 23, 27, 28, 31) . It is not entirely clear, however, how PP2A impacts this cascade in vivo. Indirect evidence suggesting a role for PP2A in the regulation of ERKs has been obtained by treatment of adipocyte cells with okadaic acid, which is a specific inhibitor of PP2A and PP1 (27) . Exposure of these cells to concentrations of okadaic acid which preferentially inhibit PP2A results in an increase in cellular MAP kinase activity. This effect seems to be specific for adipocyte cells, however, since no such effect is observed when fibroblasts are treated with okadaic acid.
Recently, it has been shown that the simian virus 40 (SV40) small tumor antigen (small t) binds to PP2A and inhibits its ability to dephosphorylate a variety of phosphoproteins in vitro, including ERK2 and MEK1 (40, 42, 43, 47, 55) . It has also been shown that expression of small t in the SV40-permissive cell line CV-1 leads to an increase in the activity of ERK2 and MEK1 and ultimately causes these cells to proliferate (47) . These effects appear to be dependent on the ability of small t to bind to PP2A, since deletion of the portion of small t that interacts with PP2A abolishes its ability to stimulate ERK2 and MEK1 activity as well as promote cell growth. Since the only known biochemical function of small t is to bind PP2A and thereby alter its substrate specificity, these results suggest that PP2A may serve to downregulate cellular ERK and MEK activity.
Previously, we have shown that ERK activity is required for the activation of AP-1 in REF52 fibroblasts by wild-type H-Ras, tetradecanoyl phorbol acetate (TPA), and serum (20) . (34) . Cells were stained for injected rat IgG by using a rhodamine-conjugated donkey anti-rat antibody (Jackson) as described previously (3, 20) . For the fos-chloramphenicol acetyltransferase (CAT) and TRElacZ expression studies, both the fos-CAT and TRE-lacZ plasmids were injected at 200 jig/ml. CAT and lacZ expression were detected by indirect immunofluorescence as described previously (3) . Injected cells were detected by indirect immunofluorescent staining for a coinjected guinea pig IgG (5 mg/ml; Sigma), using an AMCA-conjugated donkey anti-guinea pig IgG (Jackson) as described previously (3). All cells were analyzed and photographed with a Zeiss Axiophot epifluorescence microscope as previously described (3).
RESULTS
We have used short-term transcription assays (20) to determine whether expression of small t in REF52 cells is sufficient to activate AP-1 on its own or in conjunction with various growth-associated kinases. Accordingly, we have microinjected eukaryotic expression constructs encoding small t, ERK1, MEK1, and a constitutively active form of c-Raf-1 (BXB) (9) into the nuclei of quiescent REF52 fibroblasts along with an AP-1-responsive reporter plasmid (TRE-lacZ). Previous work has shown that injection of eukaryotic expression plasmids into the nuclei of these cells results in the detectable expression of the encoded protein by direct immunofluorescence within 30 min of injection in approximately 80% of the injected cells and that expression is maintained for at least 24 h after injection (3) . Furthermore, expression from reporter constructs such as the TRE-lacZ plasmid can be reliably detected 2 to 3 h after injection by staining with the chromogenic substrate X-Gal (20) . It should be noted that intense 13-Gal staining with X-Gal often interferes with the indirect immunofluorescent staining for a coinjected marker antibody used to detect injected cells. Since REF52 cells have no endogenous 13-Gal activity, however, darkly staining cells must have been injected and are treated as such in this study.
In quiescent REF52 cells, injection of the TRE-lacZ plasmid typically results in 13-Gal expression in 10 to 15% of the injected cells. This background activity is not significantly enhanced by expression of any level of small t (Fig. 1A) . Similarly, expression of ERK1, MEK1, or BXB either alone or in any combination tested does not activate AP-1 (data not shown). However, coexpression of small t and ERK1, small t and MEK1, or small t and BXB results in a strong induction of AP-1 activity within 3 h of injection (Fig. 1C, E TRE-lacZ (150 ,ug/ml) and rat IgG (5 mg/ml): (A and B) pCEP4/Smt (60 ,ug/ml); (C and D) pCEP4/Smt (60 ,ug/ml) and pCEP4/ERK1 (60 p.g/ml); (E and F) pCEP4/Smt (60 ,ug/ml) and pCEP4/MEK1 (100 pug/ml); (G and H) pCEP4/Smt (60 ,ug/ml) and pBXB (30 ,ug/ml).
BXB to activate AP-1 is dependent on the presence of the PP2A binding domain of small t since expression of a small t mutant lacking this domain (mut 3) (50) either alone or in combination with these kinases does not increase AP-1 activity ( Fig. 2A to C) . This finding suggests that small t must interact with PP2A in order to affect AP-1 activity.
To test whether this effect was specific for the AP-1-responsive construct, we coinjected small t and either ERK1, MEK1, or BXB with a lacZ reporter plasmid which is controlled by a multimer of the CRE (CRE-lacZ) (25, 26, 38 K52R ERK2 were coexpressed with small t and BXB, AP-1 activation by these constructs was abolished. Coexpression of wild-type ERK1 (as a control) with small t and BXB only slightly inhibited AP-1 activation (Fig. 2D) . Similarly, the induction of AP-1 activity by coexpression of small t and MEKi was inhibited by coexpression of K71R ERK1 and K52R ERK2 but not by coinjection of an equivalent amount of wild-type ERK1 vector (Fig. 2B) . Thus, these experiments suggest that the activation of AP-1 by either small t and BXB or small t and MEK1 depended on the activity of endogenous ERKs.
To test whether the activation of AP-1 by small t and BXB depended on the activity of endogenous MEKs, we coexpressed either wild-type MEKI or a kinase-deficient splice variant of MEKi (MEK3) with small t and BXB (57) . activation caused by small t and BXB was abolished by coexpression of MEK3 but only partially inhibited by coexpression of MEKi (Fig. 2D) . No inhibition was observed when the pCEP4 expression vector lacking MEK cDNAs was coinjected. Though it is not clear why coexpression of wild-type MEK1 partially inhibited small t-BXB-mediated AP-1 activation, the complete inhibition observed with coexpressed MEK3 suggests that endogenous MEK activity is required for the increase in AP-1 activity. The inhibition of small t-BXB-mediated AP-1 activation by coexpression of K71R ERK1 and K52R ERK2 together, or MEK3 alone, was also not due to a nonspecific inhibition of lacZ expression, since expression of these kinasedeficient constructs had no effect on the activation of the CRE-lacZ reporter plasmid stimulated by 8- (30, 37) . p62T F, or Elk-1, is a member of the ternary complex which binds to the SRE in the c-fos promoter and allows for the activation of c-fos transcription by serum and individual growth factors (50) . We examined whether coexpression of small t and ERK1 could activate the c-fos promoter by coinjecting afos-CAT reporter plasmid along with the small t and ERK1 expression vectors. This fos-CAT construct contains the first 711 bp of the human c-fos promoter, including the SRE, and has been shown to recapitulate cellular c-fos expression in vivo (20, 54) . Activation of the fos-CAT plasmid was detected by indirect immunofluorescent staining for expressed CAT protein. As an internal control in these same cells, we coinjected the TRE-lacZ reporter plasmid, which is strongly induced by coexpression of small t and ERK1. p-Gal expression was assayed in these experiments by indirect immunofluorescent staining for ,3-Gal protein. Expression of ERK1 alone did not significantly activate the fos-CAT or TRE-lacZ reporter plasmids (Fig. 3G to I ). However, coexpression of small t and ERK1 led to a strong activation of the fos-CAT construct (Fig. 3C) . Staining for lacZ showed that the TRE-lacZ construct was also strongly induced in these same cells (Fig. 3B) . Similarly, small t and ERK1 synergized to activate an SRE-lacZ reporter plasmid (data not shown). On the other hand, coexpression of small t mut 3 with ERK1 did not significantly induce either the fos-CAT or TRE-lacZ reporter plasmid (Fig. 3D to F) . Since ERK1 has been shown to directly phosphorylate and activate the p62TCF transcription factor, these data imply that coexpression of small t and ERKI leads to an activation of ERK1 kinase activity. Furthermore, since small t mut 3 was unable to synergize with ERK1 to induce the c-fos promoter, this activation appears to be dependent on the ability of small t to interact with PP2A. These experiments also indicate that the activation of ERK1 by small t can result in the enhancement of SRE-as well as TREregulated promoters.
Sontag et al. have recently shown that the introduction of small t alone into the SV40-permissive cell line CV-1 stimulates endogenous MEK and ERK activity and also promotes cell growth (47) . Given these results, we decided to test whether expression of small t alone was sufficient to activate AP-1 in these cells. As shown in Fig. 4A , expression of wild-type small t alone led to the induction of AP-1 activity in these cells. This induction required the small t domain which interacts with PP2A, since expression of small t mut 3, which does not interact with PP2A, did not significantly activate AP-1 (Fig. 4B) . Interestingly, expression of wild-type ERK1 alone in these cells strongly activates the TRE-lacZ construct (Fig. 4C) . Moreover, this activation was not significantly enhanced by the coexpression of small t with ERK1 (Fig. 4D) (21, 23, 49) . The ability of this complex to transactivate the c-fos gene, in turn, has been shown to depend on the phosphorylation of p62TCF (Elk-1) by ERKs (35) . Thus, the activation of the c-fos promoter following small t and ERK1 coexpression demonstrates that the effects of small t on transcription are not limited to AP-1-responsive promoters and also include SREregulated genes. Thus, these data suggest that other genes whose promoter activity is dependent on ERK activity may be activated by coexpression of small t and ERK1.
Because others have observed that expression of small t Previous work has demonstrated that expression of SV40 large T is sufficient to transform cycling but not resting cells (5, 6, 8, 11, 14, 19, 36, 37, 41, 45, 46) . Transformation can occur in resting cells, however, if either small t is coexpressed or the cells are treated with phorbol esters. One interpretation of this data is that small t functions by stimulating cell growth, thereby promoting stable transformation by large T. The observations described here suggest that small t accomplishes this by inhibiting the ability of PP2A to downregulate the activity of serum-responsive kinases such as MEK and ERK (47) , thereby stimulating gene expression from TRE-and SRE-regulated promoters.
Several groups have cloned isoforms of a dual-specificity phosphatase from mammalian cells that dephosphorylate phosphotyrosine as well as phosphoserine-and phosphothreonine-containing substrates (10, 24, 29, 48) . Among these is the protein encoded by the immediate-early gene 3CH134, or MKP-1 (48) . The finding that activated ERK2 is an excellent substrate for MKP-1 as well as the observation that constitutive expression of MKP-1 inhibits ERK activation strongly suggests that MKP-1 acts in vivo as an ERK phosphatase. In light of this finding, it is tempting to speculate that PP2A isoforms function in vivo as MEK phosphatases. We are currently investigating this possibility.
